Suraksha Diagnostic Limited — Investor Meet, 27-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Suraksha Diagnostic reported FY26 revenue of **INR 313.6 Cr** (up 22.5% YoY) and EBITDA of **INR 98.6 Cr** (up 15.8% YoY), with blended EBITDA margins at 31.8%. PAT grew 1.4% to **INR 31.4 Cr**. Management highlighted mature centers maintain strong 36-37% EBITDA margins. The company served 1.37 million patients, performing 8.16 million tests.

For FY27, Suraksha plans to add 13 new centers (5 hubs, 8 spokes) across West Bengal, Bihar, Tripura, and Jharkhand with a **INR 70 Cr** capex. It targets ~15% revenue growth and 33% EBITDA margins, aiming for 35% mid-term. Strategic focus includes genomics, AI integration, and enhancing patient experience. New centers are expected to breakeven at a center level within 5-12 months.